List view / Grid view
Therapeutic monoclonal antibodies are proven and effective treatment options but many of the ‘low-hanging fruit’ therapeutics have already been identified.
More research into tuberculosis is now possible with the development of an optimisied mouse model that exhibits the same blood immune response to Mycobacterium tuberculosis infection as humans.
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
AbCellera and Eli Lilly have announced their partnership to develop, manufacture and distribute antibody treatments for the COVID-19 coronavirus.
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
A new monoclonal antibody has been discovered which disassociates bacterial biofilms and stops bacteria from entering into circulation has been tested in mice.
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
Researchers have discovered that an antibody which targets the CD36 protein prevents Tregs from protecting tumours against immunotherapies in mouse models.
Research has found that after stroke in mice, B cells migrate to far regions of the brain that control motor functions, indicating their role in recovery.
More effective drugs could be developed due to a new technique that has allowed scientists to decipher how millions of individual cells are communicating with each other on miniature tumours grown in a lab.
Research has shown that human metapneumovirus uses RNA methylation to hide from the immune system and that knocking out this methylation creates a mutant strain which acts like a vaccine.
Scientists have discovered three major pro-inflammatory mediators that drive capillary loss and identified drug combinations to prevent the degeneration of these tiny blood vessels.
Researchers in the United States have used particles from the tobacco mosaic virus (TMV) to produce a new much-needed malaria vaccine.
